Published in Medical Letter on the CDC and FDA, May 29th, 2005
Study 1: Mutations in pfmdr1 associated with chloroquine resistance incur a fitness cost in Plasmodium falciparum.
According to a study from Australia, "Efforts to control malaria worldwide have been hindered by the development and expansion of parasite populations resistant to many first-line antimalarial compounds. Two of the best-characterized determinants of drug resistance in the human malaria parasite Plasmodium falciparum are pfmdr1 and pfcrt, although the mechanisms by which resistance is mediated by these genes is still not clear."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA